Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy

被引：27
|
作者：
Krause, AS [1 ]
Weihrauch, MR [1 ]
Bode, U [1 ]
Fleischhack, G [1 ]
Elter, T [1 ]
Heuer, T [1 ]
Engert, A [1 ]
Diehl, V [1 ]
Josting, A [1 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany
来源：
LEUKEMIA & LYMPHOMA | 2002年 / 43卷 / 11期
关键词：
MTX; carboxypeptidase; lymphoma; rescue;
D O I：
10.1080/1042819021000032953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
High-dose methotrexate (RDMTX) is a component of many cancer treatment regimens. Despite careful management, delayed renal clearance, followed by extremely high serum levels with potentially life-threatening toxicity can occur. In the present study, we report our results of carboxypeptidase-G(2) (CPDG(2)) rescue in 8 patients with delayed methotrexate elimination and renal impairment after HDMTX therapy for lymphoma or osteosarcoma. A dose of 50U/kg CPDG2 was administered. MTX plasma levels decreased rapidly and recovery of renal function was observed in all patients. No patient developed severe WHO grade 4 MTX toxicity. CPDG2 provides an alternative route of MTX elimination by converting it to inactive and non-toxic metabolites. CPDG(2), rescue was well tolerated, safe and very effective in preventing severe or life-threatening MTX toxicity.
引用
收藏
页码：2139 / 2143
页数：5
相关论文
共 50 条
  • [31] Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment
    Kataoka, Tatsuo
    Sakurashita, Hiroshi
    Kajikawa, Kazuya
    Saeki, Yasuyuki
    Taogoshi, Takanori
    Matsuo, Hiroaki
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (10) : 1195 - 1202
  • [32] Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy
    Inose, Ryo
    Takahashi, Katsuyuki
    Nanno, Satoru
    Hino, Masayuki
    Nagayama, Katsuya
    JOURNAL OF CHEMOTHERAPY, 2019, 31 (01) : 30 - 34
  • [33] HIGH-DOSE METHOTREXATE WITH A SAFE RESCUE PROGRAM
    DECKER, DA
    EDMONSON, JH
    GILCHRIST, GS
    KOVACH, JS
    OFFORD, JR
    TAYLOR, WF
    ONCOLOGY, 1981, 38 (05) : 262 - 264
  • [34] HIGH-DOSE METHOTREXATE WITH FOLINIC ACID RESCUE
    BENDER, JF
    GROVE, WR
    FORTNER, CL
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1977, 34 (09): : 961 - 965
  • [35] THYMIDINE RESCUE OF HIGH-DOSE METHOTREXATE IN HUMANS
    HOWELL, SB
    ENSMINGER, WD
    KRISHAN, A
    FREI, E
    CANCER RESEARCH, 1978, 38 (02) : 325 - 330
  • [36] THYMIDINE REQUIREMENTS FOR THE RESCUE OF PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE
    HOWELL, SB
    HERBST, K
    BOSS, GR
    FREI, E
    CANCER RESEARCH, 1980, 40 (06) : 1824 - 1829
  • [37] KINETICS OF 7-HYDROXY-METHOTREXATE AFTER HIGH-DOSE METHOTREXATE THERAPY
    ERTTMANN, R
    BIELACK, S
    LANDBECK, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 15 (02) : 101 - 104
  • [38] PHARMACOKINETICS OF ERYTHROCYTE METHOTREXATE AFTER HIGH-DOSE METHOTREXATE
    SCHALHORN, A
    SAUER, H
    WILMANNS, W
    STUPPPOUTOT, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (01) : 65 - 69
  • [39] DELAYED LEUCOVORIN RESCUE AFTER HIGH DOSE METHOTREXATE (HDMTX) IN CHILDREN
    HOLCENBERG, J
    CAMITTA, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 180 - 180
  • [40] Delayed elimination of methotrexate treated with carboxypeptidase G2 in a child with Burkitt lymphoma
    Dailly, E.
    Corradini, N.
    Drouard, L.
    Veyrac, G.
    Louvigne, C.
    Victorri-Vigneau, C.
    Azoulay, C.
    Mechinaud, F.
    Jolliet, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 22 - 22
12345